Back to search

Article

Molecular profiling of XPO1 inhibitor and gemcitabine-nab-paclitaxel combination in cellular and LSL-Kras G12D/+; Trp53 fl/+; Pdx1-Cre (KPC) pancreatic cancer model

2022-03-09

Abstract excerpt

The majority of pancreatic ductal adenocarcinoma (PDAC) patients experience disease progression while on treatment with gemcitabine and nab-Paclitaxel (GemPac) treatment indicating the need for more effective combinations for this recalcitrant disease. Earlier we showed that nuclear exporter protein exportin 1 (XPO1) is a valid therapeutic target in PDAC and the selective inhibitor of nuclear export (SINE) selinex...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
62b631e1-f2a4-50a5-b06f-aee40c6ad6c6
DOI
10.1101/2022.03.08.481108
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Molecular profiling of XPO1 inhibitor and gemcitabine-nab-paclitaxel combination in cellular and LSL-Kras G12D/+; Trp53 fl/+; Pdx1-Cre (KPC) pancreatic cancer modelDOI 10.1101/2022.03.08.481108
Co-targeting KRAS and Exportin1 as an effective therapeutic strategy for KRASG12D mutant pancreatic ductal adenocarcinomaSemantic proximity
Inhibitor of the nuclear transport protein XPO1 enhances the anticancer efficacy of KRAS G12C inhibitors in preclinical models of KRAS G12C mutant cancersSemantic proximity
Loss of p53 tumor suppression function drives invasion and genomic instability in models of murine pancreatic cancerSemantic proximity
CircERC1 facilitates chemoresistance through inhibiting pyroptosis and remodeling extracellular matrix in pancreatic cancerSemantic proximity
A Phase II Trial of an Extended-Release siRNA Implant Targeting KRASG12D/V in Locally Advanced Pancreatic Cancer.Semantic proximity
Inhibiting NR5A2 targets stemness in pancreatic cancer by disrupting SOX2/MYC signaling and restoring chemosensitivitySemantic proximity
Pooled CRISPR screening in pancreatic cancer cells implicates co-repressor complexes as a cause of multiple drug resistance via regulation of epithelial-to-mesenchymal transitionSemantic proximity
The past, present, and future of CRM1/XPO1 inhibitorsSemantic proximity
Targeting XPO1-Dependent Nuclear Export in Cancer.Semantic proximity
Impact of Pan-Cancer Analysis of The Exportins Family on Prognosis, The Tumour Microenvironment and Its Potential Therapeutic EfficacySemantic proximity
E3 ubiquitin ligase ASB8 promotes selinexor-induced proteasomal degradation of XPO1Semantic proximity
A Targeted Octahedral DNA Nanostructure Co-delivers siME3 and Doxorubicin to Enhance Collateral Lethality in ME2-Deficient Pancreatic CancerSemantic proximity
Select a neighboring publication to make it the new centre.